KPV is not FDA-approved for any indication. No human clinical trial has been conducted. All published evidence comes from cell culture experiments and animal models. KPV is available as a research peptide and through some compounding pharmacies, but its safety, efficacy, and pharmacokinetics in humans have not been established through the clinical trial process that FDA approval requires.

Melanocortin Immune Regulation

KPV: The Three-Amino-Acid Anti-Inflammatory

12 min read|March 22, 2026

Melanocortin Immune Regulation

3 amino acids

KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, retains the parent hormone's anti-inflammatory potency while bypassing melanocortin receptors entirely.

Dalmasso et al., Gastroenterology, 2008

View as image

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide with well-documented anti-inflammatory properties. It inhibits NF-kB, reduces proinflammatory cytokines, and suppresses immune cell recruitment across multiple tissue types.^[1] But alpha-MSH also activates melanocortin receptors that drive skin pigmentation, sexual arousal, and appetite changes, effects that limit its therapeutic use. In the early 2000s, researchers discovered that the last three amino acids of alpha-MSH, the tripeptide KPV (lysine-proline-valine), retain the parent hormone's full anti-inflammatory activity through a completely different mechanism: direct entry into cells via the peptide transporter PepT1, followed by intracellular inhibition of NF-kB nuclear translocation.^[2] This separation of anti-inflammatory function from melanocortin receptor signaling is what makes KPV distinct from other melanocortin peptides and their immune regulatory roles. For a deeper look at how KPV specifically targets the NF-kB pathway, see KPV and the NF-kB Pathway.

Key Takeaways

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH that retains full anti-inflammatory activity without activating melanocortin receptors or causing pigmentation (Getting et al., 2003)
KPV enters cells through the peptide transporter PepT1, expressed on intestinal epithelial cells, macrophages, T cells, and B lymphocytes, making it active in gut and immune tissues (Dalmasso et al., Gastroenterology, 2008)
KPV inhibits NF-kB activation by stabilizing IkB-alpha and blocking p65 nuclear translocation through competition at the importin-alpha3 binding site (Kelly et al., 2006)
In colitis models, oral KPV reduced intestinal inflammation through PepT1-mediated uptake in colonocytes, demonstrating oral bioactivity for a peptide (Dalmasso et al., 2008)
KPV reduced polymorphonuclear leukocyte accumulation in crystal-induced peritonitis to a degree comparable to full-length alpha-MSH (Getting et al., 2003)

From Alpha-MSH to KPV: Stripping a Hormone to Its Active Core

Alpha-MSH is cleaved from the precursor protein proopiomelanocortin (POMC), the same precursor that produces ACTH and beta-endorphin. Its anti-inflammatory properties were first characterized in the 1990s, when Catania et al. demonstrated that alpha-MSH modulates NF-kB activation and proinflammatory cytokine production across multiple immune cell types.^[3]

The question was which part of the 13-amino-acid sequence carries the anti-inflammatory activity. The answer came in stages:

The "core" sequence (residues 6-9: His-Phe-Arg-Trp) is the melanocortin receptor binding pharmacophore. It drives pigmentation, appetite, and sexual effects through MC1R, MC3R, MC4R, and MC5R.
The C-terminal tripeptide (residues 11-13: Lys-Pro-Val, or KPV) carries anti-inflammatory activity through a mechanism independent of melanocortin receptors.

Getting et al. (2003) demonstrated this dissection directly. In a crystal-induced peritonitis model, both KPV and full-length alpha-MSH reduced polymorphonuclear leukocyte (PMN) accumulation in the peritoneal cavity. The selective MC1R agonist MS05 did not reduce PMN accumulation, despite binding MC1R effectively. This proved that KPV's anti-inflammatory mechanism operates outside the classical melanocortin receptor pathway.^[4]

Luger et al. (2003) reviewed the broader implications, noting that alpha-MSH and its fragments represent a new class of anti-inflammatory agents with potential applications in skin, eye, bowel, and joint diseases.^[5] The practical advantage of KPV over full-length alpha-MSH is clear: three amino acids instead of thirteen, no melanocortin receptor activation, no pigmentation or appetite changes, and potentially oral bioavailability.

The NF-kB Mechanism: How KPV Works Inside Cells

NF-kB is the master transcription factor for inflammatory gene expression. In unstimulated cells, NF-kB (primarily the p65/RelA subunit) is held in the cytoplasm by its inhibitor, IkB-alpha. Inflammatory signals (TNF-alpha, IL-1, LPS) trigger IkB-alpha phosphorylation and degradation, freeing p65 to translocate to the nucleus and activate hundreds of inflammatory genes.

KPV interrupts this process at two levels:

IkB-alpha stabilization: KPV prevents the degradation of IkB-alpha, keeping p65 sequestered in the cytoplasm. Kelly et al. (2006) demonstrated that immobilized GKPV (the tetrapeptide including the adjacent glycine residue) inhibited TNF-alpha-stimulated NF-kB activity and stabilized IkB-alpha in a manner independent of melanocortin receptor signaling or cyclic AMP elevation.^[6]

Nuclear import blockade: Even when p65 escapes IkB-alpha, it must be actively transported into the nucleus through the importin-alpha/beta pathway. Research has identified that KPV competes with p65 for binding to importin-alpha3, specifically at armadillo domains 7 and 8. This competition physically prevents p65 from entering the nucleus, blocking inflammatory gene transcription at the final step.^[7]

This dual mechanism (stabilizing the inhibitor and blocking nuclear import) makes KPV a particularly effective NF-kB inhibitor because it works at two independent steps in the activation cascade.

PepT1: How a Tripeptide Gets Inside Cells

One of the most surprising findings about KPV is its transport mechanism. Melanocortin peptides (alpha-MSH, ACTH) act through cell-surface melanocortin receptors. KPV does not. Instead, it enters cells through PepT1 (SLC15A1), a proton-coupled oligopeptide transporter that normally absorbs di- and tripeptides from digested food in the small intestine.^[2]

Dalmasso et al. (2008) published the definitive study in Gastroenterology. They demonstrated that:

PepT1 mRNA and protein are expressed not only in intestinal epithelial cells but also in macrophages, T lymphocytes, and B lymphocytes
KPV is actively transported into Caco2-BBE cells (an intestinal epithelial model) and immune cells via PepT1
KPV inhibited NF-kB activation and reduced proinflammatory cytokine production in these cells
In mouse models of colitis (DSS-induced and TNBS-induced), oral KPV reduced intestinal inflammation with efficacy comparable to standard anti-inflammatory treatments
The anti-inflammatory effect was abolished when PepT1 was knocked down, confirming the transporter's essential role

The oral activity is particularly notable. Most peptides are destroyed by gastric acid and intestinal proteases before they can reach their target. KPV's tiny size (three amino acids, molecular weight ~342 Da) and PepT1-mediated uptake allow it to survive transit and enter colonocytes directly from the intestinal lumen. This makes KPV's application in colitis mechanistically elegant: the peptide is delivered exactly where the inflammation occurs, absorbed through a transporter that is upregulated during inflammation (PepT1 expression increases in inflamed intestinal tissue), and acts intracellularly on NF-kB.

Systemic Anti-Inflammatory Effects

While the intestinal data are the most detailed, KPV's anti-inflammatory effects extend beyond the gut.

Peritonitis: Getting et al. (2003) showed that intraperitoneal KPV reduced PMN recruitment in crystal-induced peritonitis, a model of acute sterile inflammation. The effect was dose-dependent and comparable in magnitude to full-length alpha-MSH.^[4]

Bronchial inflammation: Research has demonstrated that melanocortin-related peptides including KPV inhibit cellular and systemic inflammation in human bronchial epithelial cells, with evidence for MC3R involvement in some but not all of these effects, suggesting KPV may use both receptor-dependent and receptor-independent pathways depending on cell type.

Vascular calcification: Zhang et al. (2024) developed carrier-free nanodrugs combining KPV with rapamycin (RAPA) that self-assembled into nanoparticles for vascular calcification therapy. The KPV component provided anti-inflammatory protection while RAPA addressed the calcification process, demonstrating that KPV's anti-inflammatory properties can be harnessed in combination therapies for cardiovascular disease.^[8]

Brzoska et al. (2010) reviewed the broader anti-inflammatory landscape of alpha-MSH C-terminal peptides, concluding that KPV and related fragments affect NF-kB activation, adhesion molecule expression, inflammatory cytokines, chemokine receptor signaling, and T-cell differentiation across tissue types.^[7] The favorable physicochemical properties of these small peptides (stability, cell permeability, oral potential) position them as a distinct drug class from both full-length melanocortin peptides and conventional anti-inflammatory drugs.

How KPV Compares to Other Anti-Inflammatory Approaches

KPV occupies an unusual position in the anti-inflammatory landscape:

Agent	Mechanism	Receptor Required	Oral Active	Pigmentation
Alpha-MSH	MC1R/MC3R/MC4R signaling	Yes	No	Yes
KPV	PepT1 transport, NF-kB inhibition	No	Yes (in models)	No
NSAIDs	COX-1/COX-2 inhibition	No	Yes	No
Anti-TNF biologics	TNF-alpha neutralization	No	No	No
Corticosteroids	Glucocorticoid receptor	Yes	Yes	No

KPV targets NF-kB directly, which sits upstream of most inflammatory mediators (TNF-alpha, IL-1, IL-6, COX-2, iNOS). This is mechanistically broader than COX inhibitors (NSAIDs) or TNF-alpha neutralization (biologics), but also means KPV could theoretically suppress beneficial inflammatory responses alongside pathological ones. This concern applies to all NF-kB inhibitors and has not been addressed in the KPV literature.

The comparison to other melanocortin peptides is informative. Afamelanotide, the FDA-approved alpha-MSH analog for erythropoietic protoporphyria, works primarily through MC1R to stimulate eumelanin production. It has anti-inflammatory effects but also causes significant skin darkening. KPV offers anti-inflammatory activity without the pigmentation or the melanocortin receptor signaling that drives side effects.

Limitations of the Evidence

The KPV evidence base is entirely preclinical. No human clinical trial has tested KPV for any indication. The colitis data, while published in Gastroenterology (a top-tier journal), are from mouse models (DSS and TNBS colitis) that imperfectly model human inflammatory bowel disease.

The PepT1-mediated uptake mechanism has been demonstrated in cell culture and animal models, but human pharmacokinetics have not been characterized. Whether oral KPV achieves therapeutic concentrations in human colonic tissue, and whether it survives human gastrointestinal transit at useful levels, is unknown.

KPV's stability in biological fluids is a concern for any tripeptide. While PepT1 transport provides an elegant absorption mechanism, peptidases in the gut lumen, brush border, and circulation could degrade KPV before it reaches its intracellular target. No published study has reported KPV plasma half-life in humans.

The NF-kB inhibition mechanism, while well-characterized biochemically, raises theoretical safety questions. NF-kB is essential for immune defense against infections, wound healing, and cell survival. Chronic or systemic NF-kB inhibition could impair these functions. Whether KPV's effects are sufficiently localized (e.g., to the gut lumen via oral delivery) to avoid systemic immunosuppression is an unanswered question.

The regulatory status of KPV is ambiguous. It is sold as a "research peptide" and used in compounding pharmacy formulations, but it is not FDA-approved for any indication and has no IND (Investigational New Drug) application on file for clinical trials.

The Bottom Line

KPV is the C-terminal tripeptide of alpha-MSH that retains full anti-inflammatory potency through a mechanism entirely independent of melanocortin receptors. It enters cells via the PepT1 transporter and inhibits NF-kB activation by stabilizing IkB-alpha and blocking p65 nuclear import. Preclinical data show efficacy in colitis, peritonitis, and vascular inflammation models, with oral bioactivity demonstrated in mice. No human clinical trial has been conducted, and pharmacokinetics, safety, and efficacy in humans remain unknown.

Frequently Asked Questions

KPV is a tripeptide (lysine-proline-valine) that consists of the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite being only three amino acids long, it retains the full anti-inflammatory activity of the 13-amino-acid parent hormone. KPV works by entering cells through the PepT1 transporter and inhibiting NF-kB, the master switch for inflammatory gene expression, without activating melanocortin receptors or causing pigmentation changes (Dalmasso et al., Gastroenterology, 2008).

KPV inhibits NF-kB activation through two mechanisms. First, it stabilizes IkB-alpha, the protein that keeps NF-kB trapped in the cytoplasm. Second, it competes with the p65 subunit of NF-kB for binding to importin-alpha3, physically blocking nuclear import. Together, these actions prevent NF-kB from reaching the nucleus and activating inflammatory genes. KPV enters cells through the PepT1 peptide transporter, not through melanocortin receptors (Kelly et al., 2006; Brzoska et al., 2010).

In mouse models of colitis, oral KPV reduced intestinal inflammation through PepT1-mediated uptake in colonocytes (Dalmasso et al., 2008). This is unusual for a peptide, as most are degraded by digestive enzymes. KPV's tiny size (three amino acids) and uptake through a food-peptide transporter allow it to survive intestinal transit in animal models. Whether this translates to humans is unknown; no human pharmacokinetic study has been published.

KPV is derived from alpha-MSH but functions through a completely different mechanism. Alpha-MSH activates melanocortin receptors (MC1R, MC3R, MC4R) on cell surfaces, causing pigmentation, appetite changes, and anti-inflammatory effects. KPV bypasses these receptors entirely, entering cells through PepT1 and inhibiting NF-kB directly. This means KPV produces anti-inflammatory effects without the skin darkening, sexual arousal, or appetite changes associated with melanocortin receptor activation (Getting et al., 2003).

Preclinical research has tested KPV in models of colitis (intestinal inflammation), peritonitis (abdominal inflammation), bronchial inflammation, and vascular calcification. The strongest data are in colitis models, where oral KPV reduced intestinal inflammation through direct uptake by inflamed colonocytes (Dalmasso et al., 2008). Researchers have proposed potential applications in inflammatory bowel disease, inflammatory skin conditions, allergic asthma, and arthritis, but none have been tested in human trials (Luger et al., 2003).